This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Publication digest

Read time: 15 mins
Last updated:10th Nov 2021
Published:10th Nov 2021

Take a deep dive into our publication digests to learn more about RET inhibitors and their impact on the treatment and management of non-small cell lung cancer (NSCLC) and thyroid cancers.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest